US 9382327
Anti-CD20 antibodies and methods of use
granted A61KA61K2039/505A61K39/39541
Quick answer
US patent 9382327 (Anti-CD20 antibodies and methods of use) held by VACCINEX, INC. expires Mon Jun 30 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- VACCINEX, INC.
- Grant date
- Tue Jul 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 30 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 9
- CPC classes
- A61K, A61K2039/505, A61K39/39541, A61K39/39558, A61P